High mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma

World Journal of Gastroenterology

Volumn 18, Issue 48, 2012, Pages 7319-7326

  Tang, Hua Rong ^a   Luo, Xian Qin ^a   Xu, Gang ^a   Wang, Yan ^a   Feng, Zhi Jun ^a   Xu, Hui ^a   Shi, Ya Wei ^a   Zhang, Qin ^a   Wu, Li Guang ^a   Xue, Chun Quan ^a   Wang, Cheng Wei ^a   Wu, Chao Yang ^a  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Cell cycle; Cell proliferation; Gastric adenocarcinoma; High mobility group box 3; Prognosis

Indexed keywords

HIGH MOBILITY GROUP B3 PROTEIN; MESSENGER RNA; SHORT HAIRPIN RNA;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RNA INTERFERENCE; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY;

EID: 84884197810     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i48.7319     Document Type: Article

References (30)

1. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006; 12: 17-20
2. Vaccari T, Beltrame M, Ferrari S, Bianchi ME. Hmg4, a new member of the Hmg1/2 gene family. Genomics 1998; 49: 247-252
3. Agresti A, Bianchi ME. HMGB proteins and gene expression. Curr Opin Genet Dev 2003; 13: 170-178
4. Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 2010; 1799: 101-113
5. Nemeth MJ, Kirby MR, Bodine DM. Hmgb3 regulates the balance between hematopoietic stem cell self-renewal and differentiation. Proc Natl Acad Sci USA 2006; 103: 13783-13788
6. Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM, Chang HY, Shurtleff SA, Downing JR, Cleary ML. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009; 4: 129-140
7. Petit A, Ragu C, Della-Valle V, Mozziconacci MJ, LafagePochitaloff M, Soler G, Schluth C, Radford I, Ottolenghi C, Bernard OA, Penard-Lacronique V, Romana SP. NUP98HMGB3: a novel oncogenic fusion. Leukemia 2010; 24: 654-658
8. Staal FJ, de Ridder D, Szczepanski T, Schonewille T, van der Linden EC, van Wering ER, van der Velden VH, van Dongen JJ. Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia 2010; 24: 491-499
9. Bao G, Qiao Q, Zhao H, He X. Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol 2010; 8: 52
10. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-388
11. Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, Nakasato M, Lu Y, Hangai S, Koshiba R, Savitsky D, Ronfani L, Akira S, Bianchi ME, Honda K, Tamura T, Kodama T, Taniguchi T. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009; 462: 99-103
12. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18: 1427-1431
13. Pourhoseingholi MA, Moghimi-Dehkordi B, Safaee A, Hajizadeh E, Solhpour A, Zali MR. Prognostic factors in gastric cancer using log-normal censored regression model. Indian J Med Res 2009; 129: 262-267
14. Wang W, Li YF, Sun XW, Chen YB, Li W, Xu DZ, Guan XX, Huang CY, Zhan YQ, Zhou ZW. Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer 2010; 29: 923-930
15. Biglarian A, Hajizadeh E, Kazemnejad A, Zayeri F. Determining of prognostic factors in gastric cancer patients using artificial neural networks. Asian Pac J Cancer Prev 2010; 11: 533-536
16. Calcagno DQ, Guimarães AC, Leal MF, Seabra AD, Khayat AS, Pontes TB, Assumpção PP, De Arruda Cardoso Smith M, Burbano RR. MYC insertions in diffuse-type gastric adenocarcinoma. Anticancer Res 2009; 29: 2479-2483
17. Park JM, Ryu WS, Kim JH, Park SS, Kim SJ, Kim CS, Mok YJ. Prognostic factors for advanced gastric cancer: stagestratified analysis of patients who underwent curative resection. Cancer Res Treat 2006; 38: 13-18
18. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, Steelman LS. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 2008; 9: 614-630
19. Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol 2008; 18: 545-551
20. Romano S, Mallardo M, Romano MF. FKBP51 and the NF-κB regulatory pathway in cancer. Curr Opin Pharmacol 2011; 11: 288-293
21. Czyzewska J, Guzińska-Ustymowicz K, Pryczynicz A, Kemona A, Bandurski R. Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer. Folia Histochem Cytobiol 2009; 47: 289-296
22. Lazǎr D, Tǎban S, Sporea I, Dema A, Cornianu M, Lazǎr E, Goldiş A, Vernic C. Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol 2010; 51: 655-661
23. Mangham DC, Rowlands DC, Newbold KM, Reynolds GM, Fielding JW, Hallissey MT. Expression of proliferating cell nuclear antigen (PCNA) in gastric carcinoma: no evidence for prognostic value. J Clin Pathol 1994; 47: 473-474
24. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32
25. Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010; 116: 2856-2867
26. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529
27. Pazo Cid RA, Antón A. Advanced HER2-positive gastric cancer: Current and future targeted therapies. Crit Rev Oncol Hematol 2012 Sep 25; Epub ahead of print
28. Terada K, Kitayama A, Kanamoto T, Ueno N, Furukawa T. Nucleosome regulator Xhmgb3 is required for cell proliferation of the eye and brain as a downstream target of Xenopus rax/Rx1. Dev Biol 2006; 291: 398-412
29. Terada K, Furukawa T. Sumoylation controls retinal progenitor proliferation by repressing cell cycle exit in Xenopus laevis. Dev Biol 2010; 347: 180-194
30. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-267